Original language | English (US) |
---|---|
Pages (from-to) | 9-13 |
Number of pages | 5 |
Journal | Personalized Medicine |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - 2019 |
Keywords
- genetic testing
- genomic
- genomic medicine
- universal cancer screening
- universal tumor screening
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Implementing universal cancer screening programs can help sustain genomic medicine programs. / Rahm, Alanna Kulchak; Bellcross, Cecelia; Cragun, Deborah et al.
In: Personalized Medicine, Vol. 17, No. 1, 2019, p. 9-13.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Implementing universal cancer screening programs can help sustain genomic medicine programs
AU - Rahm, Alanna Kulchak
AU - Bellcross, Cecelia
AU - Cragun, Deborah
AU - Duquette, Debra
AU - Hampel, Heather
AU - Heald, Brandie
N1 - Funding Information: All authors are noncompensated members of the Lynch Syndrome Screening Network (LSSN) Board of Directors. AK Rahm acknowledges NIH funding from the National Cancer Institute (NCI) Beau Biden CancerMoonshot Initiative (R01CA211723 - Implementing Universal Lynch Syndrome Screening Across Multiple Organizations: Identifying Strategies to Facilitate and Maintains Programs in Different Organizational Contexts); no grant funding or data was used in the production of this commentary. B Heald serves on the Advisory Board for Invitae. Funding Information: All authors are noncompensated members of the Lynch Syndrome Screening Network (LSSN) Board of Directors. AK Rahm acknowledges NIH funding from the National Cancer Institute (NCI) Beau Biden Cancer Moonshot Initiative (R01CA211723 – Implementing Universal Lynch Syndrome Screening Across Multiple Organizations: Identifying Strategies to Facilitate and Maintains Programs in Different Organizational Contexts); no grant funding or data was used in the production of this commentary. B Heald serves on the Advisory Board for Invitae. H Hampel serves on the following Scientific/Medical Advisory Boards: Invitae, Genome Medical, Promega. She reports stock in Genome Medical and consults for 23 and Me. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
PY - 2019
Y1 - 2019
KW - genetic testing
KW - genomic
KW - genomic medicine
KW - universal cancer screening
KW - universal tumor screening
UR - http://www.scopus.com/inward/record.url?scp=85076876458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076876458&partnerID=8YFLogxK
U2 - 10.2217/pme-2019-0126
DO - 10.2217/pme-2019-0126
M3 - Review article
C2 - 31797715
AN - SCOPUS:85076876458
SN - 1741-0541
VL - 17
SP - 9
EP - 13
JO - Personalized Medicine
JF - Personalized Medicine
IS - 1
ER -